Harmony Biosciences Holdings, Inc.

This filing signals a strategic leadership evolution at Harmony Biosciences: the appointment of Peter Anastasiou as COO formalizes a shift toward strengthening internal operational execution, leveraging his extensive biotech leadership background at Capsida and Lundbeck. His simultaneous resignation from the Board resolves potential governance conflicts arising from holding both executive and director roles, reinforcing separation of oversight and management duties. The addition of Troy Ignelzi — a seasoned CFO with IPO, financing, and M&A experience across Karuna, Rapport, and CinCor — directly enhances the Board’s financial acumen and audit/compensation committee capabilities, particularly valuable as the company advances its CNS pipeline and commercial strategy. Antonio Gracias’ planned departure after nearly nine years, including tenure as Compensation Committee chair, reflects routine board refreshment rather than distress, and his replacement by Ignelzi (and pending election of Geno Germano) indicates a deliberate effort to broaden strategic and capital markets expertise. Anastasiou’s employment agreement includes substantial equity ($3.7M fair value), structured vesting, and robust severance protections — signaling strong commitment to retention and continuity during a critical growth phase. Collectively, these changes position Harmony for more disciplined operational scaling and enhanced board-level stewardship of long-term value creation, especially as it navigates post-approval commercialization and pipeline development in rare neurological disorders.